Female vaginal ecosystem is thought to have been modulated by co-evolutionary processes occurring between microbial and human hosts. A healthy vaginal ecosystem is dominated by Lactobacillus, while the vaginal tract can be infected by diverse pathogens which result in aerobic vaginitis (AV), Vulvovaginal Candidiasis (VVC), Bacterial Vaginosis (BV), Cytolytic vaginitis (CV), Trichomonas Vaginitis (TV), Urinary tract infections (UTI), human papillomavirus (HPV), Human Immunodeficiency Virus (HIV), other sexually transmitted diseases and gynecological oncology et al. Although there is plenty of correlational research describing the relationship between microbiota dysbiosis and gynecological disease, the microbiota-based clinical intervention research is still limited, which requires systematically target-based screening.
The urinary tract, previously considered a sterile body niche, has been recognized as an important repository of plenty of microbes. And now researchers realize the importance of vaginal microbita in gynecological health. Although it is fully accepted that the vaginal microbiota is relevant to gynecological health and we started to focus on the specific causality, there are still many issues remaining to be resolved. Firstly, it is necessary to draw more robust conclusions based on a larger clinical sample size, and data of different levels to screen the microbiota targets using data mining and bioinformatics tools. Secondly, the potential benefits of prebiotics, probiotics, vaginal microbiota transplantation (VMT) and other live biotherapeutic products (LBPs) on the health of women need to be elucidated, which supports further studies to accumulate evidence covering their clinical applications, either as preventive or therapeutic agents.
In this Research Topic, we encourage submissions of both Original Research and Review articles of research and clinical applications that address these existing challenges in gynecological disease from the angle of the vaginal microecosystem.
1. Vaginal microecology disorder and its correlation with different kinds of gynecological diseases, such as AV, BV, VVC, TV, UTI, HIV, HPV and gynecological oncology
2. The clinical diagnosis of microbiota pathogenic factor associated with gynecological disease, no matter whether there are clinical interventions.
3. The clinical intervention tools in gynecological diseases, such as prebiotics, probiotics, vaginal microbiota transplantation or other live biotherapeutic products.
4. The isolation, identification and functional screening of vaginal probiotics to ensure the function and safety of specific bacterial species.
Female vaginal ecosystem is thought to have been modulated by co-evolutionary processes occurring between microbial and human hosts. A healthy vaginal ecosystem is dominated by Lactobacillus, while the vaginal tract can be infected by diverse pathogens which result in aerobic vaginitis (AV), Vulvovaginal Candidiasis (VVC), Bacterial Vaginosis (BV), Cytolytic vaginitis (CV), Trichomonas Vaginitis (TV), Urinary tract infections (UTI), human papillomavirus (HPV), Human Immunodeficiency Virus (HIV), other sexually transmitted diseases and gynecological oncology et al. Although there is plenty of correlational research describing the relationship between microbiota dysbiosis and gynecological disease, the microbiota-based clinical intervention research is still limited, which requires systematically target-based screening.
The urinary tract, previously considered a sterile body niche, has been recognized as an important repository of plenty of microbes. And now researchers realize the importance of vaginal microbita in gynecological health. Although it is fully accepted that the vaginal microbiota is relevant to gynecological health and we started to focus on the specific causality, there are still many issues remaining to be resolved. Firstly, it is necessary to draw more robust conclusions based on a larger clinical sample size, and data of different levels to screen the microbiota targets using data mining and bioinformatics tools. Secondly, the potential benefits of prebiotics, probiotics, vaginal microbiota transplantation (VMT) and other live biotherapeutic products (LBPs) on the health of women need to be elucidated, which supports further studies to accumulate evidence covering their clinical applications, either as preventive or therapeutic agents.
In this Research Topic, we encourage submissions of both Original Research and Review articles of research and clinical applications that address these existing challenges in gynecological disease from the angle of the vaginal microecosystem.
1. Vaginal microecology disorder and its correlation with different kinds of gynecological diseases, such as AV, BV, VVC, TV, UTI, HIV, HPV and gynecological oncology
2. The clinical diagnosis of microbiota pathogenic factor associated with gynecological disease, no matter whether there are clinical interventions.
3. The clinical intervention tools in gynecological diseases, such as prebiotics, probiotics, vaginal microbiota transplantation or other live biotherapeutic products.
4. The isolation, identification and functional screening of vaginal probiotics to ensure the function and safety of specific bacterial species.